China Medicine Corp. engages in the development, manufacture, and sale of western pharmaceuticals, traditional Chinese medicines, and other healthcare products. The company is headquartered in Guangzhou, Guangdong and currently employs 281 full-time employees. The company went IPO on 2005-06-23. The firm is engaged in the production and distribution of prescription and over the counter (OTC) drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The firm is developing a number of products for a range of indications, including oncology, high blood pressure and the removal of toxins from food and animal feeds. The firm's products include Shuangdan Capsules, Houerhuan Anti-inflammatory Capsules, Shugan Yipi Granules, Danggui Tiaojing Granules, Huangzao Granules, Pingfeng Shengmai Capsules, Danqi Tablets and Naodesheng Tablets. The firm also offers a range of dietary supplements, which include BeThin Tablets, Refrelizer Herbal Tea, LifeFull Herbal Tea and Relaxetox Herbal Tea. Shuangdan Capsules are indicated for the treatment of stagnation of the heart blood, obstruction of qi in the chest and cardiodynia.
최신 재무제표(Form-10K)에 따르면, China Medicine Corp의 총 자산은 $0이며, 순손실입니다.
CHME의 주요 재무 비율은 무엇인가요?
China Medicine Corp의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
China Medicine Corp의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
China Medicine Corp 주요 수익원은 Wholesale Brokerage이며, 최신 수익 발표에서 수익은 1,600,427,000입니다. 지역별로는 United States이 China Medicine Corp의 주요 시장이며, 수익은 2,864,242,000입니다.